YD Bio Limited (NasdaqGM: YDES)
Health Care · Biotechnology · TW
$5.92
-12.04% today · -70.3% 1Y
YD Bio Limited (NasdaqGM: YDES) operates in the Biotechnology industry within the Health Care sector. The company is valued at $419.32M and employs 14 people.
Over the last twelve months the share price has lost 70.3%, trading between 1.70 and 22.00.
Tweenvest scores YD Bio Limited across four factors: quality 51/100, value 39/100. Its strongest factor is quality.
YDES price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $419.32M
- Revenue (TTM)
- $1.24M
- P/E
- —
- EPS
- 0.00
- Dividend yield
- —
- Beta (5Y)
- -0.16
- 52-week high
- $22.00
- 52-week low
- $1.70
- Avg volume (3M)
- —
- Shares outstanding
- 70.83M
- Employees
- 14
- Next earnings
- —
About YD Bio Limited
YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes the eyes and relieves dry eye symptoms; 3D LensMate Eye Drops, an ophthalmic solution to alleviate symptoms of dry eye syndrome, including irritation, foreign body sensation, and eye fatigue; and LSC Eye Drug/Injection, an injectable ophthalmic drug is being developed for the treatment of various retinal and macular disorders, such as age-related macular degeneration, macular edema, choroidal and subretinal neovascularization, and neovascular glaucoma. It also provides Hydrogel (Hioxifilcon A) Soft (Hydrophilic) Contact Lens, a spherical and aspherical lenses. In addition, the company supplies drugs and medical materials for clinical trials; and operates DNA methylation-based oncology testing programs. Further, it provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination, and compliance-focused support for clinical development programs to pharmaceutical and biotechnology companies. It serves corporate and retail customers. The company was founded in 2013 and is based in Taipei, Taiwan.
- ISIN
- KYG983011076
- Founded
- 2013
- Listed since
- Aug 29, 2025
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| ACRO Biomedical Co., Ltd.TPEX: 6748 | $429.72M | NT$194.50 | -8.69% |
| Prothena Corporation plcNasdaqGS: PRTA | $428.66M | $8.35 | -5.54% |
| MapLight Therapeutics, Inc.NasdaqGS: MPLT | $427.93M | $7.70 | -12.80% |
| Ovid Therapeutics Inc.NasdaqCM: OVID | $421.84M | $2.16 | -8.86% |
| Edding Genor Group Holdings LimitedSEHK: 6998 | $418.87M | HK$1.65 | -3.24% |
| Beijing Kawin Technology Share-Holding Co., Ltd.SHSE: 688687 | $412.63M | CN¥16.49 | -10.04% |
| Altimmune, Inc.NasdaqGM: ALT | $412.38M | $2.12 | -2.30% |
| Autolus Therapeutics plcNasdaqGS: AUTL | $409.89M | $1.54 | -2.53% |
Figures last refreshed Oct 18, 2026.